The prospective multicenter trial demonstrated a 91.7% complete ablation rate for hepatocellular carcinoma (HCC) near critical structures, with a technical success rate of 99.5%. Smaller tumors (<2 cm) achieved higher ablation rates compared to larger tumors (90.1% vs. 71.7%). During a median follow-up of 33.5 months, local tumor progression rates were 9.8%, 13.8%, and 15.7% at 1, 2, and 3 years, respectively, with limited adverse events reported.
Journal Article by Xu M, Zhang W (…) Jiang T et 8 al. in Int J Surg
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.